Chronic Pain News courtesy of FibroAnswers.com...

Chronic Pain News for 04-08-2005 

Chronic Pain News from Yahoo.com

Chronic Pain News from NewsTrove

Low Cost Online Share Trading Ireland - Business News, Irish Share Prices, US Stock Quotes, UK Share Prices, Stock Brokers Tips
From: NewsTrove.com

"In what the company repeatedly called a "transitional year," Pfizer executives told listeners at its annual analysts' meeting that it expects adjusted earnings of about $2 a share for 2005, compared with the $2.12 a share it earned for 2004. Net income, excluding extraordinary items, should amount to $1.16 a share this year, the pharmaceutical giant said. By 2006, the world's largest drug maker expects both earnings and sales growth to make a recovery as new products begin to add to the company's revenue."

FDA shelves Bextra
From: NewsTrove.com

"WASHINGTON - Doctors are bracing for a flood of confused patients wondering what painkillers are safe, now that the government is ordering scarier warning labels on the most popular prescription brands. At issue: whether anti-inflammatory medicines called NSAIDs - the backbone of U.S. pain treatment - raise the risk heart attacks and strokes, particularly when taken at high doses or for long periods of time. Pfizer Inc. reluctantly pulled its blockbuster painkiller Bextra off the market Thursday at the Food and Drug Administration's behest."

The Five Dumbest Things on Wall Street This Week
From: NewsTrove.com

"1. Shining Starr He's been gone barely a week now, but already retirement has been good to Hank Greenberg. Leaving AIG (AIG:NYSE) has let the longtime CEO show off a side Wall Street might not have seen before. This week a picture emerged, even as regulators and prosecutors probed AIG's accounting and business practices under his decades-long reign, of a Hank Greenberg who is downright benevolent -- even generous to a fault. This development might come as a surprise to some people. For years, Greenberg was regarded as an intimidating, exacting taskmaster who wasn't shy about shouting down employees or analysts."

Painkillers-Risk, 2nd Writethru
From: NewsTrove.com

""In Canada, since there is that voluntary withdrawal in the States, we feel that while we complete our own evaluation about this specific topic, it's the best thing to withdraw the product temporarily. And the manufacturer has agreed to that," Dr. Marc Berthiaume, Health Canada's manager of marketed pharmaceuticals, said during a media teleconference. "Health Canada is close to completing its evaluation of the coxib drugs. So it's difficult for me to predict what would have been our conclusions. . . . But it's probable that similar consideration would have applied." The move leaves only one pure cox-2 still standing, Pfizer's Celebrex."

DeWitt Era-Enterprise News Story
From: NewsTrove.com

"Pfizer's Outlook Darkens on FDA Bextra Ban By THERESA AGOVINO NEW YORK - Pfizer Inc.'s earnings are likely to slump further this year and its recently released plan to return to double-digit earnings growth in 2006 and 2007 could be in jeopardy because of Thursday's decision by federal regulators to ban the sale of Bextra, one of its blockbuster pain relievers, analysts said. The Food and Drug Administration asked Pfizer to halt the sale of Bextra, which has been linked to increased risk of heart attacks and a rare skin condition."

Click here to learn more about Fibromyalgia Answers - The Complete Guide to Understanding Fibromyalgia & How You Can Learn to Live With It.

fibromyalgia answers | privacy | terms of use